Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 1b Study of JCAR014, Autologous T Cells Engineered to Express a CD19-Specific Chimeric Antigen Receptor, in Combination With Durvalumab (MEDI4736) for Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Brief Summary: This phase Ib trial studies whether anti-CD19-chimeric antigen receptor (CAR) lentiviral vector-transduced autologous T cells (JCAR014) and durvalumab are safe in combination and can work together in treating patients with non-Hodgkin lymphoma that has returned after a period of improvement (relapsed) or has not responded to previous treatment (refractory). JCAR014 is made of each patient's immune cells (T cells) that have a new gene added to them in a laboratory, which programs them to kill lymphoma cells. Durvalumab is a type of drug called a monoclonal antibody, targeted to PD-L1 that may help immune cells attack cancer cells more effectively and thus help JCAR014 work better.


Options:
A: Arm Label: Group I (JCAR014, durvalumab) Early - Dose Level 2; Type: EXPERIMENTAL; Interventions: Biological: Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014, Drug: Cyclophosphamide, Biological: Durvalumab, Drug: Fludarabine | Arm Label: Group I (JCAR014, durvalumab) Late- Dose Level 1; Type: EXPERIMENTAL; Interventions: Biological: Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014, Drug: Cyclophosphamide, Biological: Durvalumab, Drug: Fludarabine | Arm Label: Group I (JCAR014, durvalumab) Late - Dose Level 2; Type: EXPERIMENTAL; Interventions: Biological: Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014, Drug: Cyclophosphamide, Biological: Durvalumab, Drug: Fludarabine | Arm Label: Group II (durvalumab, JCAR014) - Dose Level 1; Type: EXPERIMENTAL; Interventions: Biological: Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014, Drug: Cyclophosphamide, Biological: Durvalumab, Drug: Fludarabine | Arm Label: Group II (durvalumab, JCAR014) - Dose Level 2; Type: EXPERIMENTAL; Interventions: Biological: Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014, Drug: Cyclophosphamide, Biological: Durvalumab, Drug: Fludarabine | Arm Label: Group II (durvalumab, JCAR014) - Dose Level 3; Type: EXPERIMENTAL; Interventions: Biological: Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014, Drug: Cyclophosphamide, Biological: Durvalumab, Drug: Fludarabine | Arm Label: Group II (durvalumab, JCAR014) - Dose Level 4; Type: EXPERIMENTAL; Interventions: Biological: Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014, Drug: Cyclophosphamide, Biological: Durvalumab, Drug: Fludarabine | Arm Label: Group II (durvalumab, JCAR014) - Dose Level 5; Type: EXPERIMENTAL; Interventions: Biological: Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014, Drug: Cyclophosphamide, Biological: Durvalumab, Drug: Fludarabine | Intervention Type: BIOLOGICAL; Name: Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014; Assigned to Arm(s): Group I (JCAR014, durvalumab) Early - Dose Level 2, Group I (JCAR014, durvalumab) Late - Dose Level 2, Group I (JCAR014, durvalumab) Late- Dose Level 1, Group II (durvalumab, JCAR014) - Dose Level 1, Group II (durvalumab, JCAR014) - Dose Level 2, Group II (durvalumab, JCAR014) - Dose Level 3, Group II (durvalumab, JCAR014) - Dose Level 4, Group II (durvalumab, JCAR014) - Dose Level 5 | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): Group I (JCAR014, durvalumab) Early - Dose Level 2, Group I (JCAR014, durvalumab) Late - Dose Level 2, Group I (JCAR014, durvalumab) Late- Dose Level 1, Group II (durvalumab, JCAR014) - Dose Level 1, Group II (durvalumab, JCAR014) - Dose Level 2, Group II (durvalumab, JCAR014) - Dose Level 3, Group II (durvalumab, JCAR014) - Dose Level 4, Group II (durvalumab, JCAR014) - Dose Level 5 | Intervention Type: BIOLOGICAL; Name: Durvalumab; Assigned to Arm(s): Group I (JCAR014, durvalumab) Early - Dose Level 2, Group I (JCAR014, durvalumab) Late - Dose Level 2, Group I (JCAR014, durvalumab) Late- Dose Level 1, Group II (durvalumab, JCAR014) - Dose Level 1, Group II (durvalumab, JCAR014) - Dose Level 2, Group II (durvalumab, JCAR014) - Dose Level 3, Group II (durvalumab, JCAR014) - Dose Level 4, Group II (durvalumab, JCAR014) - Dose Level 5 | Intervention Type: DRUG; Name: Fludarabine; Assigned to Arm(s): Group I (JCAR014, durvalumab) Early - Dose Level 2, Group I (JCAR014, durvalumab) Late - Dose Level 2, Group I (JCAR014, durvalumab) Late- Dose Level 1, Group II (durvalumab, JCAR014) - Dose Level 1, Group II (durvalumab, JCAR014) - Dose Level 2, Group II (durvalumab, JCAR014) - Dose Level 3, Group II (durvalumab, JCAR014) - Dose Level 4, Group II (durvalumab, JCAR014) - Dose Level 5
B: Arm Label: Treatment; Type: EXPERIMENTAL; Interventions: Biological: lisocabtagene maraleucel | Intervention Type: BIOLOGICAL; Name: lisocabtagene maraleucel; Assigned to Arm(s): Treatment
C: Arm Label: ALL (high tumor burden) dose level 1; Type: EXPERIMENTAL; Interventions: Biological: Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes | Arm Label: ALL (high tumor burden) dose level 2; Type: EXPERIMENTAL; Interventions: Biological: Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes | Arm Label: ALL (high tumor burden) dose level 3; Type: EXPERIMENTAL; Interventions: Biological: Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes | Arm Label: ALL (low tumor burden) dose level 1; Type: EXPERIMENTAL; Interventions: Biological: Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes | Arm Label: ALL (low tumor burden) dose level 2; Type: EXPERIMENTAL; Interventions: Biological: Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes | Arm Label: CLL dose level 1; Type: EXPERIMENTAL; Interventions: Biological: Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes | Arm Label: CLL dose level 2; Type: EXPERIMENTAL; Interventions: Biological: Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes | Arm Label: CLL dose level 3; Type: EXPERIMENTAL; Interventions: Biological: Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes | Arm Label: CLL (ibrutinib) dose level 2; Type: EXPERIMENTAL; Interventions: Biological: Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes | Arm Label: NHL dose level 1; Type: EXPERIMENTAL; Interventions: Biological: Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes | Arm Label: NHL dose level 2; Type: EXPERIMENTAL; Interventions: Biological: Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes | Arm Label: NHL dose level 3; Type: EXPERIMENTAL; Interventions: Biological: Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes | Arm Label: NHL (dose dense) dose level 2; Type: EXPERIMENTAL; Interventions: Biological: Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes | Intervention Type: BIOLOGICAL; Name: Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes; Assigned to Arm(s): ALL (high tumor burden) dose level 1, ALL (high tumor burden) dose level 2, ALL (high tumor burden) dose level 3, ALL (low tumor burden) dose level 1, ALL (low tumor burden) dose level 2, CLL (ibrutinib) dose level 2, CLL dose level 1, CLL dose level 2, CLL dose level 3, NHL (dose dense) dose level 2, NHL dose level 1, NHL dose level 2, NHL dose level 3
D: Arm Label: anti-CD20-CAR T cell; Type: EXPERIMENTAL; Interventions: Biological: anti-CD20-CAR vector-transduced autologous T cells, Other: genetically engineered lymphocyte therapy | Intervention Type: BIOLOGICAL; Name: anti-CD20-CAR vector-transduced autologous T cells; Assigned to Arm(s): anti-CD20-CAR T cell | Intervention Type: OTHER; Name: genetically engineered lymphocyte therapy; Assigned to Arm(s): anti-CD20-CAR T cell

Answer: A